Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Robert A Jabulowsky"'
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e61267 (2013)
Natural killer (NK) cells are highly specialized effectors of the innate immune system that hold promise for adoptive cancer immunotherapy. Their cell killing activity is primarily mediated by the pro-apoptotic serine protease granzyme B (GrB), which
Externí odkaz:
https://doaj.org/article/ef704e3f72d1418d90548c650373682c
Publikováno v:
PLoS ONE, Vol 5, Iss 12, p e14404 (2010)
BackgroundThe apoptosis-inducing serine protease granzyme B (GrB) is an important factor contributing to lysis of target cells by cytotoxic lymphocytes. Expression of enzymatically active GrB in recombinant form is a prerequisite for functional analy
Externí odkaz:
https://doaj.org/article/9b058161300746e0baf7a7f5dc13a391
Autor:
Christoph Huber, Andreas Pinter, Heinrich Haas, Tana Omokoko, Verena Müller, Julian Sikorski, Alexandra Kemmer-Brück, Malte Stein, Inga Liebig, Claudia Tolliver, Melanie Leierer, Jessica C. Hassel, Petra Oehm, Sebastian Attig, Isabel Vogler, Evelyna Derhovanessian, Juliane Quinkhardt, Janina Caspar, Lisa Hebich, Jochen Utikal, Özlem Türeci, Carmen Loquai, Maike Gold, Roland Kaufmann, Sebastian Kreiter, Ugur Sahin, Richard Rae, Andreas Kuhn, Stephan Grabbe, Doreen Schwarck-Kokarakis, Lena M. Kranz, Matthias Miederer, Daniel Maurus, Mathias Vormehr, Mustafa Diken, Katarina Cuk, Stephanie Renken, Heidrun Mitzel-Rink, Andrea Breitkreuz, Robert A. Jabulowsky, Alexander Hohberger
Publikováno v:
Nature. 585:107-112
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-refractory tumours1,2. We are testing melano
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::303f452f94121b674c882c38aa381209
https://doi.org/10.1038/s41586-020-2537-9
https://doi.org/10.1038/s41586-020-2537-9
Autor:
Kerstin C. Reuter, Abderraouf Selmi, Christoph Huber, Sebastian Attig, Carmen Loquai, Peter Langguth, Andreas Kuhn, Özlem Türeci, Fulvia Vascotto, Heinrich Haas, Stephan Grabbe, Hossam Hefesha, Martin Meng, Yves Hüsemann, Sebastian Kreiter, Lena M. Kranz, Jessica C. Hassel, Ugur Sahin, Jan Diekmann, Janina Buck, Richard Rae, Mathias Vormehr, Mustafa Diken, Evelyna Derhovanessian, Robert A. Jabulowsky, Sandra Heesch, Christian Grunwitz, Daniel Fritz
Publikováno v:
Nature. 534:396-401
Lymphoid organs, in which antigen presenting cells (APCs) are in close proximity to T cells, are the ideal microenvironment for efficient priming and amplification of T-cell responses. However, the systemic delivery of vaccine antigens into dendritic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4414807873394f92cbda7c135f5c11e1
https://doi.org/10.1038/nature18300
https://doi.org/10.1038/nature18300
Autor:
Jochen Utikal, Sebastian Attig, Maike Gold, Melanie Leierer, Andreas Pinter, Julian Sikorski, Katarina Cuk, Evelyna Derhovanessian, Matthias Miederer, Ö. Türeci, Carmen Loquai, Heidrun Mitzel-Rink, Robert A. Jabulowsky, Ugur Sahin, Roland Kaufmann, Petra Oehm, Jessica C. Hassel, Doreen Schwarck-Kokarakis, Isabel Vogler, Stephan Grabbe
Publikováno v:
Journal of Clinical Oncology. 38:3136-3136
3136 Background: Cancer vaccines are considered unsuitable for patients with advanced tumours and have not been clinically successful. Methods: Lipo-MERIT is an ongoing phase 1/2 trial (NCT02410733) with melanoma FixVac, a liposomal RNA vaccine targe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5690a55b4aa00d44cf018af9bce6c5a
https://doi.org/10.1200/jco.2020.38.15_suppl.3136
https://doi.org/10.1200/jco.2020.38.15_suppl.3136
Autor:
Sarah Kutscher, Björn-Philipp Kloke, Cedrik M. Britten, Andrea Mahr, Richard Rae, Robert A. Jabulowsky
Publikováno v:
Cancer Immunology, Immunotherapy. 64:923-930
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6921140e641c9263aa4c9cc10e3ecad
https://doi.org/10.1007/s00262-014-1643-7
https://doi.org/10.1007/s00262-014-1643-7
Autor:
Jan-Hendrik Trösemeier, Axel V. Horn, Gerald G. Schumann, Robert A. Jabulowsky, Carsten Münk, Johannes Löwer, Kay-Martin Hanschmann, Henning Hofmann, André Berger, Sabine Klawitter, Anja Bock, Ananda Ayyappan Jaguva Vasudevan, Egbert Flory, Jeffrey S. Han, Roswitha Löwer, Ulrike Held
Publikováno v:
Nucleic Acids Research
LINE-1 (L1) retrotransposons are mobile genetic elements whose extensive proliferation resulted in the generation of ≈ 34% of the human genome. They have been shown to be a cause of single-gene diseases. Moreover, L1-encoded endonuclease can elicit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb6f44f06f408885c41f27329d8d305c
http://europepmc.org/articles/PMC3874205
http://europepmc.org/articles/PMC3874205
Publikováno v:
Antibodies, Vol 2, Iss 1, Pp 130-151 (2013)
The potential utility of immunotoxins for cancer therapy has convincingly been demonstrated in clinical studies. Nevertheless, the high immunogenicity of their bacterial toxin domain represents a critical limitation, and has prompted the evaluation o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da761ab82390f00683882582f4ceeb89
https://doi.org/10.3390/antib2010130
https://doi.org/10.3390/antib2010130
Autor:
Evelyna Derhovanessian, Christine Anft, Özlem Türeci, Roland Kaufmann, Sebastian Attig, Andreas Kuhn, Martin Meng, Stephan Grabbe, Richard Rae, Christoph Huber, Malte Stein, Felicitas Müller, Andreas Pinter, Fatih Sari, Robert A. Jabulowsky, Mustafa Diken, Alexandra Deubel, Peter Langguth, Doreen Schwarck-Kokarakis, Daniel Maurus, Claudia Guertler, Ludwig Heesen, Katharina H Schreeb, Dirk Jäger, Heidrun Mitzel-Rink, Alexandra Kemmer-Brück, Christoffer Gebhardt, Sebastian Kreiter, Klaus Kuehlcke, Ulrich Luxemburger, Jochen Utikal, Ugur Sahin, Maike Gold, Jessica C. Hassel, Heinrich Haas, Carmen Loquai, Lena M. Kranz
Publikováno v:
Cancer Research. 78:CT156-CT156
Therapeutic vaccination with tumor antigen-encoding RNAs is being investigated in various clinical trials. Typically, the RNA vaccine is administered intradermally, subcutaneously or intranodally with the intention to get expression of the encoded an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0907642e81438a71b5b48780e7c43b09
https://doi.org/10.1158/1538-7445.am2018-ct156
https://doi.org/10.1158/1538-7445.am2018-ct156
Autor:
Stephan Grabbe, Jan Diekmann, Christoph Huber, K Hartmann, Sebastian Attig, Jochen Utikal, Sebastian Kreiter, Peter Langguth, Andreas Kuhn, Carmen Loquai, Doreen Schwarck-Kokarakis, Martin Meng, Malte Stein, Robert A. Jabulowsky, Alexandra Kemmer-Brueck, Heinrich Haas, Mustafa Diken, Ugur Sahin, Klaus Kuehlcke, Oezlem Tuereci, Richard Rae, Lena M. Kranz, Jessica C. Hassel, Janina Buck, Christine Anft, Roland Kaufmann, Evelyna Derhovanessian, Daniel Fritz, Ulrich Luxemburger, Fatih Sari
Publikováno v:
Cancer Research. 77:CT034-CT034
Therapeutic vaccination with tumor antigen-encoding RNAs by local administration is currently being successfully employed in various clinical trials. Advancing from local to more efficient systemic targeting of antigen-presenting cells (APCs), we hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f69490ab401ab14dd548fe522d9b262
https://doi.org/10.1158/1538-7445.am2017-ct034
https://doi.org/10.1158/1538-7445.am2017-ct034